Patent Assignment
Reel/Frame 050886/0942
Change of Name
Recorded: 2019-10-17
Pages: 11
Assignor
PRECISION IBD, INC.
Executed: 2019-10-02
Assignee
PROMETHEUS BIOSCIENCES, INC.
3525 DEL MAR HEIGHTS ROAD #342, SAN DIEGO, CALIFORNIA, 92130
Covered Properties
(206)
Inflammatory Bowel Disease First Step Assay System
Patent:
6,218,129 →
Application:
09/079,435 →
Method of Determining Thiopurine Methyltransferase Activity
Methods of Diagnosing Liver Fibrosis
Methods of Quantifying Methotrexate Metabolites
Methods for Direct Detection of Individual Methotrexate Metabolites
Method of Determining Thiopurine Methyltransferase Acitivity
Methods of diagnosing liver fibrosis
Application:
10/504,544 →
Publication:
US US20060084057A1
Methods of Diagnosing Tissue Fibrosis
Methods of Diagnosing Inflammatory Bowel Disease
Method for optimizing thiopurine efficacy and toxicity using mass spectrometry
Application:
11/274,104 →
Publication:
US US20060216726A1
Methods of Predicting Methotrexate Efficacy and Toxicity
Application:
11/380,171 →
Publication:
US US20060286571A1
Methods of Diagnosing Inflammatory Bowel Disease
Method and System for Assisting in Diagnosing Irritable Bowel Syndrome
Patent:
7,943,328 →
Application:
11/679,149 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
11/838,810 →
Publication:
US US20080085524A1
Methods for Diagnosing Irritable Bowel Syndrome
Methods of Diagnosing Inflammatory Bowel Disease
Application:
11/841,699 →
Publication:
US US20080182280A1
Methods for Diagnosing Irritable Bowel Syndrome
Patent:
8,685,741 →
Application:
12/043,082 →
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application:
12/191,286 →
Publication:
US US20090197266A1
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application:
12/191,287 →
Publication:
US US20090197267A1
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application:
12/191,290 →
Publication:
US US20090197268A1
Methods of Predicting Methotrexate Efficacy and Toxicity
Application:
12/194,501 →
Publication:
US US20100203507A1
Methods of Predicting Methotrexate Efficacy and Toxicity
Application:
12/194,503 →
Publication:
US US20100203508A1
Addressable Antibody Arrays and Methods of Use
Application:
12/209,863 →
Publication:
US US20090081711A1
Methods for Diagnosing Irritable Bowel Syndrome
Application:
12/253,177 →
Publication:
US US20100094560A1
Crohn Disease Susceptibility Gene
Application:
12/309,635 →
Publication:
US US20100099083A1
Methods to Predict Risk for Celiac Disease by Detecting Anti-Flagellin Antibody Levels
Patent:
8,409,819 →
Application:
12/392,997 →
Methods and Agents for Evaluating Inflammatory Bowel Disease, and Targets for Treatment
Application:
12/450,478 →
Publication:
US US20100167285A1
Methods of Quantifying Methotrexate Metabolites
Application:
12/484,148 →
Publication:
US US20100159493A1
Addressable Antibody Arrays and Methods of Use
Methods for Prediction of Inflammatory Bowel Disease (Ibd) Using Serologic Markers
Application:
12/615,983 →
Publication:
US US20100129838A1
Methods of Diagnosing Tissue Fibrosis
Application:
12/695,126 →
Publication:
US US20100317022A1
Methods for Predicting Methotrexate Polyglutamate Levels Using Pharmacogenetics
Application:
12/698,966 →
Publication:
US US20100203539A1
A Method for Determining the Risk of Crohn's Disease-Related Complications
Methods for Diagnosing Irritable Bowel Syndrome
Methods of Diagnosing Inflammatory Bowel Disease
Methods of Quantifying Methotrexate Metabolites
Application:
13/158,082 →
Publication:
US US20110262948A1
Assays and Methods for the Detection of Crohn's Disease
Patent:
8,445,215 →
Application:
13/190,369 →
Citrullinated Peptides for Diagnosing and Prognosing Rheumatoid Arthritis
Inflammatory Bowel Disease Prognostics
Application:
13/283,511 →
Publication:
US US20120171672A1
Methods for Diagnosing Irritable Bowel Syndrome
Methods for Diagnosing Irritable Bowel Syndrome
Application:
13/441,658 →
Publication:
US US20120315630A1
Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Novel Genomic Biomarkers for Irritable Bowel Syndrome Diagnosis
Application:
13/479,127 →
Publication:
US US20130005596A1
Addressable Antibody Arrays and Methods of Use
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
13/686,861 →
Publication:
US US20130203053A1
Methods of Predicting Methotrexate Efficacy and Toxicity
Application:
13/709,558 →
Publication:
US US20130143215A1
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application:
13/750,282 →
Publication:
US US20130131072A1
Mobility Shift Assays for Detecting Anti-Tnf Alpha Drugs and Autoantibodies Thereto
Application:
13/797,815 →
Publication:
US US20140051184A1
Assay for Detecting Neutralizing Autoantibodies to Biologic Therapy
Application:
13/802,117 →
Publication:
US US20130266963A1
Methods for Improving Inflammatory Bowel Disease Diagnosis
Mobility Shift Assays for Detecting Anti-Tnf Alpha Drugs and Autoantibodies
Application:
13/859,664 →
Publication:
US US20130295685A1
Methods for Determining Anti-Drug Antibody Isotypes
Methods for Diagnosing Irritable Bowel Syndrome
Application:
13/891,128 →
Publication:
US US20140051594A1
HER2DELTA16 Peptides
Citrullinated Peptides for Diagnosing and Prognosing Rheumatoid Arthritis
Application:
13/952,499 →
Publication:
US US20140170683A1
Assays for Detecting Autoantibodies to Anti-Tnfalpha Drugs
Application:
13/961,841 →
Publication:
US US20140045276A1
Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Performance of a Biomarker Panel for Irritable Bowel Syndrome
Application:
14/071,581 →
Publication:
US US20140141990A1
Methods of Disease Activity Profiling for Personalized Therapy Management
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia or Cancer
Application:
14/102,432 →
Publication:
US US20140179549A1
Assays for Detecting Neutralizing Autoantibodies to Biologic Therapy
Compositions and Methods for Detecting Allelic Variants
Methods for Diagnosing Irritable Bowel Syndrome
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
14/229,715 →
Publication:
US US20150072879A1
Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Antibodies to Microbiome, Stress Factors and Mast Cell Markers as Diagnostic Markers for Ibs
Methods for Predicting and Monitoring Mucosal Healing
Application:
14/678,455 →
Publication:
US US20150355195A1
HER2DELTA16 Peptides
Pathway Specific Assays for Predicting Irritable Bowel Syndrome Diagnosis
Pathway Specific Markers for Diagnosing Irritable Bowel Syndrome
Methods for Predicting Post-Operative Recurrence of Crohn's Disease
Signaling Pathways in Tissues from Inflammatory Bowel Disease Patients
Application:
15/171,970 →
Publication:
US US20160356790A1
Biomarker Panel for Assessment of Mucosal Healing
Assays for Detecting Neutralizing Autoantibodies to Biologic Therapy
Assays for the Detection of Anti-TNF Drugs and Autoantibodies
HER2DELTA16 Peptides
Methods for Predicting Clinical Outcomes in Subjects Afflicted with Ulcerative Colitis
Application:
15/484,878 →
Publication:
US US20170219605A1
Methods for Prediction of Anti-Tnf Alpha Drug Levels and Autoantibody Formation
Antibodies Against Serotonin, Tryptophan and Kynurenine Metabolites and Uses Thereof
Application:
15/587,739 →
Publication:
US US20170240652A1
Methods for Establishing a Vedolizumab Dosing Regimen to Treat Patients with Irritable Bowel Disease
Indirect Homogeneous Mobility Shift Assays for the Detection of Biologics in Patient Samples
Pathway Specific Markers for Diagnosing Irritable Bowel Syndrome
Pathway Specific Assays for Predicting Irritable Bowel Syndrome Diagnosis
Application:
15/847,406 →
Publication:
US US20180136233A1
Pathway Specific Markers for Diagnosing Irritable Bowel Syndrome
Addressable Antibody Arrays and Methods of Use
Application:
16/036,180 →
Publication:
US US20180321254A1
Methods of Disease Activity Profiling for Personalized Therapy Management
Method of determining thiopurine methyltransferase activity
Application:
60/205,695 →
Methods of diagnosing tissue fibrosis
Application:
60/514,034 →
Methods for optimizing clinical responsiveness to chemotherapy
Application:
60/514,423 →
Methods for optimizing clinical responsiveness to low-dose anti-folate therapy
Application:
60/560,752 →
Inflammatory bowel disease assay system
Application:
60/571,216 →
Methods for predicting methotrexate polyglutamate levels using pharmacogenetics
Application:
60/580,141 →
Methods to optimize thiopurine therapy and reduce toxicity using metabolite profiling and mass spectrometry
Application:
60/628,728 →
Methods for evaluating risk associated with methotrexate therapy using pharmacogenetics
Application:
60/676,442 →
Methods for monitoring methotrexate therapy using pharmacogenomic and metabolite biomarkers
Application:
60/731,598 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
60/822,488 →
Crohn disease susceptibility gene
Application:
60/833,261 →
Crohn disease susceptibility gene
Application:
60/834,151 →
Methods of Diagnosing Irritable Bowel Syndrome
Application:
60/884,397 →
Methods of Diagnosing Intestinal Disorders
Application:
60/893,594 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
60/895,962 →
Genome-wide association scan identifites nell1 as a novel IBD disease gene and 5p13.1 as a female-specific susceptibility region for Crohn disease
Application:
60/907,543 →
Genome-wide association scan identifites NELL1 as a novel IBD disease gene and 5p13.1 as a female-specific susceptibility region for Crohn disease
Application:
60/919,953 →
Method and system for assisting in diagnosing irritable bowel syndrome
Application:
60/921,486 →
Methods of diagnosing inflammatory bowel disease
Application:
60/934,919 →
Publication:
US US20060154276A1
Addressable Antibody Arrays and Methods of Use
Application:
60/972,724 →
Methods to Predict Risk and Severity for Celiac Disease
Application:
61/031,636 →
Methods of Prediction of Inflammatory Bowel Disease (Ibd) Using Serologic Markers
Application:
61/113,537 →
Methods of Prediction of Inflammatory Bowel Disease (Ibd) Using Serologic Markers
Application:
61/118,346 →
Methods to Predict Risk and Severity for Celiac Disease
Application:
61/118,968 →
Citrullinated Peptides for Diagnosing and Prognosing Rheumatoid Arthritis
Application:
61/164,840 →
Methods of Inflammatory Bowel Disease Prognosis and Biological Response Prediction
Application:
61/169,230 →
Methods of Inflammatory Bowel Disease Prognosis and Biological Response Prediction
Application:
61/178,454 →
Methods to Predict Probability for Surgery in Crohn's Disease Patients
Application:
61/220,453 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
61/220,525 →
Diagnosis and Treatment of Early Onset Rheumatoid Arthritis
Application:
61/243,496 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
61/252,094 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/255,048 →
Diagnosis and Treatment of Early Onset Rheumatoid Arthritis
Application:
61/255,058 →
Methods to Predict Probability for Surgery in Crohn's Disease Patients
Application:
61/255,066 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
61/256,717 →
Methods for Predicting Post-Surgery Risk Associated with Ileal Pouch-Anal Anastomosis
Application:
61/259,978 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/262,877 →
Inflammatory Bowel Disease Prognostics
Application:
61/262,903 →
Methods of Diagnosing Irritable Bowel Syndrome
Application:
61/264,588 →
Novel Genomic Biomarkers for Irritable Bowel Syndrome Diagnosis
Application:
61/264,634 →
Inflammatory Bowel Disease Prognostics
Application:
61/265,324 →
Methods for Prediction of Inflammatory Bowel Disease (Ibd) Using Serologic Markers
Application:
61/265,723 →
Inflammatory Bowel Disease Prognostics
Application:
61/286,356 →
Inflammatory Bowel Disease Prognostics
Application:
61/300,787 →
Inflammatory Bowel Disease Prognostics
Application:
61/302,066 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/324,635 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
61/326,176 →
Methods for Predicting Post-Surgery Risk Associated with Ileal Pouch-Anal Anastomosis
Application:
61/334,348 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/345,567 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/351,269 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/351,837 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/354,141 →
Assays and Methods for the Detection of Crohn's Disease
Application:
61/367,328 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/389,672 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/393,581 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/393,588 →
Methods for Optimizing Therapy with Anti-Tnf Drugs
Application:
61/394,269 →
HER2DELTA16 Peptides
Application:
61/419,210 →
Performance of a Biomarker Panel for Irritable Bowel Syndrome
Application:
61/486,734 →
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia and Cancer
Application:
61/497,016 →
Methods for Optimizing Therapy with Anti-Tnf Drugs
Application:
61/505,031 →
Compositions and Methods for Detecting Allelic Variants
Application:
61/525,137 →
Methods for Optimizing Therapy with Anti-Tnf Drugs
Application:
61/528,072 →
Methods for Optimizing Therapy with Anti-Tnf Drugs
Application:
61/535,884 →
Methods for Determining Combination Therapy with Proleukin for the Treatment of Cancer
Application:
61/537,502 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/550,293 →
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia and Cancer
Application:
61/551,330 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/553,853 →
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia and Cancer
Application:
61/565,445 →
Performance of a Biomarker for Irritable Bowel Syndrome
Application:
61/566,521 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/567,096 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/570,271 →
Compositions and Methods for Detecting Allelic Variants
Application:
61/588,151 →
Assays for Measuring Anti-Tnf Drug and Anti-Drug Antibody Levels
Application:
61/622,484 →
Assays for Measuring Anti-Tnf Drug and Anti-Drug Antibody Levels
Application:
61/646,115 →
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia and Cancer
Application:
61/648,529 →
MOBILITY SHIFT ASSAYS FOR DETECTING ANTI-TNFalpha DRUGS AND AUTOANTIBODIES THERETO
Application:
61/683,681 →
Assays for Measuring Anti-Tnf Drug and Anti-Drug Antibody Levels
Application:
61/700,855 →
Assays for Measuring Anti-Tnf Drug and Anti-Tnf Drug Antibody Levels
Application:
61/716,415 →
Assays for Measuring Anti-Tnf Drug and Anti-Drug Antibody Levels
Application:
61/717,592 →
Assays for Detecting Neutralizing Autoantibodies to Biologic Therapy
Application:
61/732,251 →
Optimized Anti-TL1A Antibodies
Application:
62/662,605 →
Methods and Systems for Selection and Treatment of Patients with Inflammatory Diseases
Application:
62/664,720 →
Methods and Systems for Selection and Treatment of Patients with Inflammatory Diseases
Application:
62/681,557 →
Optimized Anti-TL1A Antibodies
Application:
62/756,494 →
Methods and Systems for Selection and Treatment of Patients with Inflammatory Diseases
Application:
62/784,179 →
GPR35 Modulators
Application:
62/796,459 →
Multi-Protein Serum Test Predicts Mucosal Healing in Children with Ileocolonic Crohn's Disease
Application:
62/775,039 →
Methods of Diagnosing Liver Fibrosis
PCT:
PCT/US2003/006038 ↗
Methods of Quantifying Methotrexate Metabolites
PCT:
PCT/US2003/027313 ↗
Method for Direct Detection of Individual Methotrexate Metabolities
PCT:
PCT/US2004/006312 ↗
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
PCT:
PCT/US2004/027851 ↗
Methods of Diagnosing Tissue Fibrosis
PCT:
PCT/US2004/035766 ↗
Methods of Diagnosing Inflammatory Bowel Disease
PCT:
PCT/US2005/016965 ↗
Methods for Predicting Methotrexate Polyglutamate Levels Using Pharmacogenetics
PCT:
PCT/US2005/020957 ↗
Method for Optimizing Thiopurine Efficacy and Toxicity Using Mass Spectrometry
PCT:
PCT/US2005/041272 ↗
Methods of Predicting Methotrexate Efficacy and Toxicity
PCT:
PCT/US2006/016246 ↗
Methods of Diagnosing Inflammatory Bowel Disease
PCT:
PCT/US2006/046136 ↗
Crohn Disease Susceptibility Gene
PCT:
PCT/US2007/074481 ↗
Methods for Diagnosing Irritable Bowel Syndrome
PCT:
PCT/US2007/075976 ↗
Methods and Agents for Evaluating Inflammatory Bowel Disease, and Targets for Treatment
PCT:
PCT/US2008/058281 ↗
Addressable Antibody Arrays and Methods of Use
PCT:
PCT/US2009/037566 ↗
Methods for Prediction of Inflammatory Bowel Disease (Ibd) Using Serologic Markers
PCT:
PCT/US2009/063924 ↗
Citrullinated Peptides for Diagnosing and Prognosing Rheumatoid Arthritis
PCT:
PCT/US2010/028946 ↗
Inflammatory Bowel Disease Prognostics
PCT:
PCT/US2010/030934 ↗
Methods for Diagnosing Irritable Bowel Syndrome
PCT:
PCT/US2010/039866 ↗
Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
PCT:
PCT/US2010/054125 ↗
Methods for Diagnosing Irritable Bowel Syndrome
PCT:
PCT/US2010/054810 ↗
Methods for Predicting Post-Surgery Risk Associated with Ileal Pouch-Anal Anastomosis
PCT:
PCT/US2010/056271 ↗
Novel Genomic Biomarkers for Irritable Bowel Syndrome Diagnosis
PCT:
PCT/US2010/058099 ↗
Methods for Improving Inflammatory Bowel Disease Diagnosis
PCT:
PCT/US2011/039174 ↗
Methods for Determining Anti-Drug Antibody Isotypes
PCT:
PCT/US2011/056777 ↗
HER2DELTA16 Peptides
PCT:
PCT/US2011/062954 ↗
Performance of a Biomarker Panel for Irritable Bowel Syndrome
PCT:
PCT/US2012/038197 ↗
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia or Cancer
PCT:
PCT/US2012/042533 ↗
Assays for Detecting Neutralizing Autoantibodies to Biologic Therapy
PCT:
PCT/US2012/045794 ↗
Compositions and Methods for Detecting Allelic Variants
PCT:
PCT/US2012/051442 ↗
Methods for Determining Combination Therapy with Il-2 for the Treatment of Cancer
PCT:
PCT/US2012/056753 ↗
Methods for Improving Inflammatory Bowel Disease Diagnosis
PCT:
PCT/US2012/061202 ↗
Methods and Systems for Selection and Treatment of Patients with Inflammatory Diseases
PCT:
PCT/US2019/029402 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Mar 27, 2007
From: DERVIEUX, THIERRY
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 019072/0502 →
Assignment of Assignor's Interest
May 10, 2007
From: LOIS, AUGUSTO; NERI, BRUCE
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 019277/0873 →
Assignment of Assignor's Interest
Sep 14, 2007
From: BARSTAD, PAUL
To: PROMETHEUS LABORATORIES, INC.
Reel/Frame 019825/0444 →
Assignment of Assignor's Interest
Sep 14, 2007
From: ROSE, STEVEN L.; OH, ESTHER; WALSH, MICHAEL J.
To: PROMETHEUS LABORATORIES, INC.
Reel/Frame 019830/0344 →
Notice of Grant of Security Interest
Sep 28, 2007
From: PROMETHEUS LABORATORIES INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 019892/0404 →
Termination of Security Interest in Patents
Oct 8, 2007
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: PROMETHEUS LABORATORIES, INC.
Reel/Frame 019920/0883 →
Assignment of Assignor's Interest
Jan 17, 2008
From: LOIS, AUGUSTO
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 020379/0161 →
Assignment of Assignor's Interest
Mar 4, 2008
From: LOIS, AUGUSTO
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 020598/0234 →
Assignment of Assignor's Interest
Jun 27, 2008
From: LOIS, AUGUSTO
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 021162/0090 →
Assignment of Assignor's Interest
Dec 19, 2008
From: DERVIEUX, THIERRY
To: PROMETHEUS LABORATORIES, INC.
Reel/Frame 022010/0400 →
Assignment of Assignor's Interest
Mar 3, 2009
From: DERVIEUX, THIERRY; WALSH, MICHAEL
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 022336/0439 →
Assignment of Assignor's Interest
Mar 3, 2009
From: DERVIEUX, THIERRY; WALSH, MICHAEL
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 022336/0243 →
Assignment of Assignor's Interest
Dec 14, 2009
From: LOIS, AUGUSTO; NERI, BRUCE
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 023648/0393 →
Notice of Grant of Security Interest in Patents
Dec 22, 2009
From: PROMETHEUS LABORATORIES INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 023679/0428 →
Assignment of Assignor's Interest
Apr 6, 2010
From: DERVIEUX, THIERRY; WALSH, MICHAEL
To: CYPRESS BIOSCIENCE, INC.
Reel/Frame 024194/0178 →
Security Agreement
Oct 12, 2010
From: EXAGEN DIAGNOSTICS, INC.
To: CYPRESS BIOSCIENCE, INC.
Reel/Frame 025126/0241 →
Assignment of Assignor's Interest
Dec 19, 2012
From: PROMETHEUS LABORATORIES INC.
To: NESTEC S.A.
Reel/Frame 029504/0740 →
Short-Form Patent Security Agreement
Oct 15, 2013
From: EXAGEN DIAGNOSTICS, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031414/0660 →
Release of Security Interest
Dec 29, 2015
From: BANK OF AMERICA, N.A.
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 037378/0464 →
Release of Security Interest
Sep 1, 2017
From: CYPRESS BIOSCIENCE INC.
To: EXAGEN DIAGNOSTICS, INC.
Reel/Frame 043747/0382 →
Release of Security Interest
Sep 7, 2017
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: EXAGEN DIAGNOSTICS, INC.
Reel/Frame 043784/0828 →
Security Interest
Sep 11, 2017
From: EXAGEN DIAGNOSTICS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 043548/0228 →
Merger
Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
Corrective Assignment to Correct the English Translation to Show the Full and Correct New Name in Section 51. Previously Recorded at Reel: 049391 Frame: 0756. Assignor(S) Hereby Confirms the Merger.
Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
Release of Security Interest
Jun 28, 2019
From: BANK OF AMERICA, N.A.
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 049626/0387 →